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Introduction 
 
Congenital bicuspid aortic valve and advanced 
age are leading risk factors for calcific aortic 
valve stenosis (CAVS), the third leading cause of 
heart disease in adults [1-3]. However, epidemi-
ological databases have helped to define other 
clinical risk factors, including smoking, male 
sex, hypertension, hypercholesterolemia, excess 
body mass index, and diabetes [4, 5].  
 
Genetic predisposition has also been suggested 
as a mechanism for CAVS development [6], al-
though few studies have elucidated the genes 
and genetic variants involved. Probst et al [7] 
demonstrated a familial aggregation for CAVS in 
western France. Polymorphisms in the vitamin D 
receptor are more common in patients with 
CAVS [8], and loss of function through mutation 
of a polymorphism in the NOTCH1 receptor ac-
celerates calcification of the valve in patients 
with CAVS and other congenital heart abnor-
malities [9, 10]. 
 
Two studies have correlated genetic lipoprotein 
abnormalities in patients predisposed to CAVS 
development [11, 12] and Nordstrom et al [13] 
demonstrated that Pvull polymorphisms in the 
estrogen receptor alpha gene are related to 
presence of aortic stenosis (AS) in postmeno-
pausal women and to lipid levels in adolescent 
females, suggesting that this polymorphism may 
influence CAVS risk by affecting lipid levels.  
 
The importance of oxidative modification of low-
density lipoprotein (LDL) in the pathogenesis of 
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Abstract: Introduction and Objectives: Paraoxonases may exert anti-atherogenic action by reducing lipid peroxidation. 
Previous studies examined associations between polymorphisms in the paraoxonase 1 (PON1) gene and develop-
ment of coronary artery disease (CAD), with inconsistent results. Given the similarities in clinical and pathophysiologi-
cal risk factors of CAD and calcific aortic valve stenosis (CAVS), we postulated a link between PON1 alleles and CAVS 
progression. Methods: We investigated the association between PON1 55 and 192 single nucleotide polymorphisms 
(SNPs), their enzyme activity, and CAVS progression assessed by aortic valve area and transvalvular peak velocity in 
67 consecutive patients with moderate CAVS and 251 healthy controls. Results: PON1 paraoxonase activity was 
higher in CAVS patients (P<0.001). The PON1 genotype Q192R SNP (P=0.03) and variant allele (R192) (P=0.01) 
frequencies differed between CAVS patients and controls. Significant association existed between PON1 enzyme 
activity, phenotypic effects of PON1 192 genotype polymorphisms, and CAVS progression, but not between PON1 55 
and high-density lipoprotein (P=0.44) or low-density lipoprotein cholesterol (P=0.12), between 192 genotype and high
-density lipoprotein (P=0.24) or low-density lipoprotein cholesterol (P=0.52). Conclusion: The PON1 genotype Q192R 
SNP has an important effect on CAVS disease progression. This study helps outline a genotype-phenotype relation-
ship for PON1 in this unique population. 
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atherosclerosis is well recognized [14, 15]. As 
an anti-atherogenic mediator, high-density lipo-
protein (HDL), besides its key role in reverse 
cholesterol transport [16], protects itself and 
LDL against oxidation and reduces lipoprotein-
associated peroxides[17-19]. The antioxidant 
property of HDL has been attributed, in part, to 
the paraoxonase 1 (PON1) enzyme [15, 18-20]. 
PON1 is an aryldialkylphosphatase synthesized 
in the liver and transported in systemic circula-
tion exclusively in association with an HDL sub 
fraction containing apolipoproteins (apo) A-I and 
apoJ [21-23]. Serum PON1 activity is inversely 
related to coronary artery disease (CAD), hyper-
cholesterolemia, and diabetes [23, 24].  
 
Previous studies [23] reported two protein poly-
morphisms in PON1 Q192R and L55M that ex-
ert significant effects on PON1 activity. We 
typed these two polymorphisms in all subjects 
and determined allele frequencies. Individually, 
both polymorphisms exert significant effects on 
all substrate activities. The previous studies 
showed that QQ individuals had lower PON1 
activity compared to RR, whereas LL individuals 
had higher activity for all substrates compared 
to MM. The M55 variant is associated with 
lower PON1 activity levels, probably as a result 
of a large imbalance with the Q192 PON1 vari-
ants [24, 25]. The variability of PON1 activity 
towards paraoxon is partly determined by poly-
morphisms in the paraoxonase gene located on 
chromosome 7 between q21.3 and 22.1. Of 
these, the codon 192 polymorphism produces 
two alloenzymes, with low and high activity, re-
spectively [26, 27]. In the high-activity alloen-
zyme, glutamine (Q allele) is replaced by argin-
ine (R allele) at codon 192. In several but not all 
studies, the R192 allele was associated with 
CAD risk [28-33] and adverse lipoprotein profile 
[28, 32, 34-36]. PON1 has other common poly-
morphisms at codon 55 [Leu (L)/Met (M)] that 
correlate with enzyme activity [26, 37]. In-
creased enzyme activity has been associated 
with higher HDL levels in some populations, but 
not in all studies [38]. The PON 192 and 55 
polymorphisms also have been associated with 
risk of ischemic stroke [39].  
 
In the past decade, several studies have investi-
gated the association between the single nu-
cleotide polymorphisms (SNPs) of the PON gene 
cluster and CAD susceptibility, but have yielded 
apparently conflicting results. The PON1 geno-
type Gln192Arg (Q192R) SNP was significantly 
associated with stroke in CARE trial patients 
[25] and PON1 activity is lower in patients with 
CAVS and inversely correlated with CAVS sever-
ity [26]. Inconsistent results could be due to 
insufficient power, the small effect of the poly-
morphism on CHD risk, and/or false-positive 
results. A recent meta-analysis suggested a 
weak association, overall, between Q192R SNP 
and CHD risk [27]. Altogether, these clinical 
studies focused on Q192R PON1 SNP suggest 
that a certain genetic background may be re-
lated to higher risk of developing CAVS. We 
chose PON1 as a candidate marker to test the 
hypothesis that common PON1 genetic variants 
could influence aortic valve calcification and 
CAVS progression. The study aimed to evaluate 
(1) the allele frequency of Q192R and L55M 
SNPs, (2) the effects of this polymorphism on 
serum lipoprotein variables, and (3) the relation-
ship between Q192R and L55M PON1 gene 
SNPs and PON1 enzyme activity in CAVS pro-
gression in our patient population.  
 
Methods 
 
Research ethics 
 
The study complied with the Helsinki declara-
tion and the Pedro Hispano Hospital Institu-
tional Review Board (Matosinhos, Oporto, Portu-
gal) approved the protocol (IRB-22352). All par-
ticipants were fully informed and provided 
signed consent before enrollment.   
 
Study population 
 
Participants in the prospective Rosuvastatin 
Affecting Aortic Valve Endothelium (RAAVE) 
study were asymptomatic patients with moder-
ate AS, defined as an aortic valvular area (AVA) 
of 1.0 to 1.5 cm2. We selected 255 consecutive, 
statin-naïve, new AS referrals to our inpatient 
and outpatient cardiology clinic [28] and ex-
cluded those with history of CAD (myocardial 
infarction and/or angiographically demon-
strated coronary artery stenosis), aortic valve 
surgery, congenital cardiac disease (bicuspid 
aortic valve), statin therapy, active or chronic 
liver disease, or currently taking an angiotensin-
converting enzyme inhibitor. No other medica-
tions were contraindicated, including other anti-
hypertensives, oral hypoglycemics, or insulin. 
Other exclusion criteria were echocardiographic 
evidence of rheumatic mitral valve disease, aor-
tic regurgitation, subaortic obstruction, and 
creatinine concentration ≥2.0 mg/dL (to mini-
mize the risk of hypercalcemia as a potential 
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confounding factor).  
 
Of the remaining 135 eligible participants, 14 
were unsuitable due to technical problems with 
initial echocardiography or difficulties in obtain-
ing medical history. Sufficient DNA was avail-
able for genetic analysis of 67 of the 121 as-
ymptomatic AS patients finally included, before 
randomization to treatment. To estimate 10-
year cardiovascular risk of death, we included a 
control group of 251 healthy volunteers (age 
>45 years, without CAD or AS, with low cardio-
vascular risk based on sex, age, smoking status, 
blood pressure, and total cholesterol). Data ob-
tained for all participants included age, sex, 
smoking history, and presence of hypercholes-
terolemia, arterial hypertension (>140/90 Hg), 
and diabetes. At inclusion, no participant had 
detectable evidence of inflammatory, neoplas-
tic, metabolic, or vascular disease in an initial 
history, examination, or routine tests. Patients 
received standard clinical care throughout the 
study. 
 
Biochemistry 
 
Blood was drawn after 12-hour fasting for rou-
tine clinical biochemistry in the Pedro Hispano 
Hospital laboratory, following standard institu-
tional protocols. In-hospital audit had previously 
demonstrated sample result variability between 
5% and 15% for these assays (data not shown). 
 
PON1 activity 
 
Serum PON1 paraoxonase (PON1-para) activity 
was determined using paraoxon (Aldrich Chemi-
cal Co, St. Louis, MO) as previously described 
[29]. Briefly, the assay buffer was prepared 
from 0.132 M Tris–HCl, pH 8.5, and 1.32 mM 
CaCl2. Each set of assays used 6 mM freshly 
prepared paraoxon substrate solution (120 mM 
paraoxon in acetone diluted with 0.132 mM Tris
–HCl). The assay tube contained 152 µl Tris 
buffer, 8 µl serum (1:2 diluted with water), and 
40 µl 6-mM paraoxon. The reaction was initi-
ated at 37.8°C by adding the substrate solu-
tion; absorbance was continuously monitored at 
405 nm. A molar extinction coefficient of 18.05 
x 103 was obtained and used to calculate activ-
ity, and units were expressed as U/L. 
 
PON1 genotyping 
 
Genetic samples were taken following 10 min-
utes of supine rest and immediately prior to 
echocardiography. Whole blood samples were 
collected, stored, and frozen at -80°C. Extrac-
tion was done using phenol-chloroform purifica-
tion, and DNA was eluted in 50 μl TE. Polymor-
phisms were genotyped using a TaqMan allelic 
discrimination assay. Q192R (rs662) and L55M 
(rs854580) PON1 polymorphisms were typed 
using primers and probes from the Applied Bio-
systems Predesigned Drug Metabolism Geno-
typing Assays program (Applied Biosystems, 
Foster City, CA). Genotyping was done with the 
ABI Prism 7900HT Sequence Detection System 
and typing errors were reduced using Simwalk2 
(Sobel and Lange, 1996). The Q192R genotype 
was 97% concordant with previous assess-
ments based on PON1 activity status [30] and, 
in a subset of unrelated individuals, both poly-
morphisms were in Hardy-Weiberg equilibrium. 
 
Echocardiography 
 
Comprehensive transthoracic echocardiograms 
were performed and reported in a single central 
echocardiography laboratory (Acuson Sequoia 
C512, Siemens Healthcare, Erlangen, Germany) 
by either of two experienced cardiologists spe-
cialized in echocardiography (LM and IB). Imme-
diate inter-observer review determined which 
studies should be repeated to maintain quality 
control. Everyone involved in performing and 
interpreting echocardiograms was blinded to 
patient treatment status. Hemodynamic pro-
gression was assessed using serial echocardio-
graphic studies at 6-month intervals. 
 
Standard Doppler recordings were made of the 
left ventricular outflow tract and aortic valve 
from multiple views to obtain peak transvalvular 
jet velocity (Vmax), mean and peak gradients, 
and AVA in accordance with international guide-
lines [31, 32]. Left atrial volume relative to body 
surface area was estimated from end-systolic 
measurements [33-37]. Reproducibility of the 
echocardiography observations by the two cardi-
ologists was assessed in a 30-patient subset. 
All echocardiography parameters examined 
showed intra-class coefficient correlation (ICC) 
between 0.962 and 0.989 (intra-observer) and 
between 0.955 and 0.992 (inter-observer). Con-
ventional Doppler and tissue Doppler imaging 
(TDI) parameters [38, 39] had good intra- and 
inter-observer coefficients of reproducibility 
(1.56-9.02). Coefficients of variation and repro-
ducibility were, for intra-observer variability, 
1.88% and 0.16 m/sec for Vmax and 3.89% and 
0.06 cm2 for AVA, respectively, for observer 1 
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and 2.01% and 0.14 m/sec for Vmax, and 
3.25% and 0.08 cm2 for AVA, respectively, for 
observer 2, and for inter-observer variability, 
2.0% and 0.14 m/sec for Vmax and 2.91% and 
0.04 cm2 for AVA, respectively.  
 
Statistical analysis 
 
Patient characteristics are presented as 
mean±standard deviation (SD) for normally dis-
tributed continuous variables; categorical vari-
ables are expressed as frequencies 
(percentages) and non-normally distributed con-
tinuous variables as the median (1st-3rd inter-
quartile ranges). Continuous variables were as-
sessed usingKolmogorov-Smirnov test to verify 
the assumption of normality.  
 
Reproducibility was assessed with the Bland 
and Altman method [40, 41] and results ex-
pressed as a coefficient of reproducibility (twice 
the SD of the differences). Differences in base-
line characteristics between CAVS patients and 
controls were compared with independent t-
tests for normally distributed continuous vari-
ables, Mann-whitney U tests for non-normally 
distributed continuous variables, and chi-square 
for categorical variables. 
 
Differences between PON1 genotypes groups 
and lipid profile were compared using one-way 
ANOVA. The relationship between enzyme activ-
ity and alleles was studied using one-way 
ANOVA followed by Tukey HSD multiple compari-
son test. Differences between AS patients and 
controls in the distribution of genotype and al-
lele frequencies and estimates of Hardy-
Weinberg equilibrium were tested using chi-
squared. Logistic regression modeling deter-
mined the association between the independ-
ent effect of the Q192R SNP and the effect of 
interaction between genotype, PON1 activity, 
and other covariates on lipids and CAVS pro-
gression. All statistical analysis was performed 
using SPSS, version 17.0.1 for Windows SPSS 
Inc, Chicago, IL). Significance level was .05 for 
all analyses. 
 
Results 
 
Population characteristics 
 
Patients and controls were chosen from con-
secutive referrals to our inpatient and outpa-
tient cardiology clinic. Social and clinical differ-
ences between the two groups have been pub-
lished in detail elsewhere [28]; a summary is 
provided in Table 1. In addition to having similar 
serum lipid levels, the groups did not differ with 
respect to sex (male: AS group 62.7% vs. con-
trols 49.0%, P=0.320) or other established car-
diovascular risk factors. The AS group was more 
likely to have elevated total cholesterol 
(227.0±52.0 md/dL vs. 189.1±44.1 mg/dL in 
controls; P=0.004), elevated HDL-cholesterol 
(53.4±10.7 md/dL vs. 43.7±11.4. mg/dL, re-
spectively; P=0.001), and diabetes mellitus 
(44.8% vs. 11.8%, respectively; P=0.001). 
 
Baseline cardiac function 
 
Both groups had similar normal left ventricular 
systolic function (P=0.067), with ejection frac-
tion 54.3±2.1% in AS patients and 55.6±4.4% 
in controls (Table 1). End-diastolic long axis di-
ameter was 51.4±5.7 mm in the AS group vs. 
52.3±4.2 mm in controls (P=0.311). End-
systolic long-axis diameter was 33.4±4.8 mm in 
the AS group vs. 34.6±3.9 mm in controls 
(P=0.165). There was no difference between 
groups in left ventricular mass (P=0.091) or left 
atrial volume (P=0.625). 
 
Paraoxonase1 55 and 192 polymorphism and 
the presence of CAVS 
 
The PON1 55 and 192 polymorphisms had al-
lele frequencies of 51.8% for L and 83.2% for R 
in AS patients, and 42% and 72.9%, respec-
tively, in controls (Table 2). Analysis of Q192R 
distributions in the different PON1 genotypes 
showed significant prevalence in the frequency 
of R alleles in the AS patients (P=0.01); in addi-
tion, 62.7% were carriers of RR variant allele vs. 
45.0% of controls (P=0.03). With respect to 
PON1 L55M, there were no significant differ-
ences in allelic frequency and allelic variants 
(LL, MM and LM) between groups (P>0.05) 
(Table 2). For both PON1 55 and 192 polymor-
phisms, good agreement was found between 
the observed and expected genotype frequen-
cies according to the Hardy-Weinberg equilib-
rium (data not shown). 
 
Linkage disequilibrium 
 
The analysis of linkage disequilibrium between 
PON1 polymorphisms is presented in Table 3. 
We observed, as have other studies, a strong 
(D>90%) genetic linkage disequilibrium         
PON1 and calcific aortic valve stenosis progression  
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between PON1 polymorphisms at the promoter 
and coding regions. 
 
Paraoxonase1 55 and 192 polymorphisms and 
lipid profile 
Mean levels of serum lipoproteins for Q192R 
and L55M are presented in Table 4. After ad-
justing for age, sex, and blood pressure, the Q 
and R alleles were not associated with signifi-
cantly increased HDL cholesterol (P=0.44); the 
Table 1. Baseline Clinical Characteristics 
Characteristic All patients 
n=318 
CAVS patients 
n=67 
Controls 
n=251 
P 
Clinical         
Age (years) 73.7 ±9.2 73.4±8.9 73.8±9.1 0.831 
Male 165(51.9%) 42(62.7%) 123(49.0%) 0.070 
BMI (kg/m2) 28.3 ±5.0 29.2 ±4.5 28.1±4.9 0.210 
Arterial hypertension 118(37.1%) 20(29.9%) 98(39.1 %) 0.088 
Diastolic BP (mmHg) 74.9±12.9 77.5±13.0 74.2±12.8 0.192 
Systolic BP(mmHg) 148.8±23.7 153.1±21.9 147.6±24.1 0.171 
Diabetes 60 (18.9%) 30(44.8%) 30(12.0%) 0.001* 
Sinus rhythm 271(85.2%) 60(89.6%) 211(84.0 %) 0.284 
Heart rate (beats/min) 71.5±12.8 74.3±13.1 70.7±12.6 0.138 
Biochemical         
Total Cholesterol (mg/dL) 197.1±48.3 227.0±52.0 189.1±44.1 0.004 
HDL (mg/dL) 45.8±11.9 53.4±10.7 43.7±11.4 0.001 
LDL (mg/dL) 126.5±42.0 145.7±42.2 121.3±40.5 0.078 
BNP (pg/mL) 39.9 (15.9-91.8) 37.9 (15.9-87.3) 45.3 (23.4-91.8) 0.405 
PON1 activity (µmol/min/mL) 155.0±39.6 230.8±1.20 134.7±6.48 <0.001 
  
Echocardiography 
        
End-diastolic long-axis di-
ameter (mm) 
52.1±4.6 51.4±5.7 52.3±4.2 0.311 
End-systolic long-axis di-
ameter (mm) 
34.3±4.1 33.4±4.8 34.6±3.9 0.165 
Ejection fraction (%) 55.3±4.1 54.3±2.1 55.6±4.4 0.067 
Left ventricular mass index 
(g/m2) 
78.4±22.4 81.9±29.1 77.5±20.2 0.091 
Left atrial volume/SA (mL/
m2) 
36.0±11.4 36.3±10.4 35.9±11.7 0.625 
  
Values are means±standard deviations for normally distributed continuous variables, medians (interquartile range) 
for non-normally distributed continuous variables, and frequencies (percentages) for categorical variables. Abbrevia-
tions: CAVS, calcific aortic valvular stenosis; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein 
cholesterol; LDL, low-density lipoprotein cholesterol; BNP, brain natriuretic peptide; PON1, Paraoxonase 1; SA, sur-
face area. 
 
Table 2.  Frequency of Paraoxonase 1 (PON1) 55 and 192 Polymorphisms 
Polymorphism 
(frequencies and percentages) 
Genotype CAVS patients 
n=67            % 
P 
PON1: Q192R         0.03 
  RR 42  62.7 113 45.0   
  QR 20 29.9 98 39.1   
  QQ 5  7.5 40  15.9   
  Allele Frequency       0.01 
  R 124  83.2 344  72.9   
 Q 25   16.8 128     27.1   
PON1: L55M         >0.05 
  LL 20   29.9 54      21.6   
  MM 20  29.9 94   37.3   
  LM 27  40.3 103  41.1   
  Allele Frequency       >0.05 
  L 67 50.8 211  42.0   
  M 65  49.2 291   58.0   
Controls 
n=251            % 
PON1 and calcific aortic valve stenosis progression  
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same was true for L and M alleles (P=0.24). 
Neither Q nor R allele genotypes were associ-
ated with serum levels of total cholesterol 
(P=0.25 and P=0.34, respectively) or LDL cho-
lesterol (P=0.12 and P=0.52, respectively). 
 
Paraoxonase 1 55 and 192 polymorphisms and 
PON1 enzyme activity 
 
The carriers of RR variant allele demonstrated a 
significantly higher AVA reduction than the carri-
ers of QQ variant allele (one-way ANOVA, 
Tukey’s HSD test p=0.04) and QR variant allele 
(one-way ANOVA, Tukey’s HSD test p=0.02). 
Moreover the carriers of QR variant allele have 
showed a significantly lower Vmax increase than 
QQ allele (one-way ANOVA, Tukey’s HSD test 
p=0.04) and RR variant allele (one-way ANOVA, 
Tukey’s HSD test p=0.04) (Table 5).  
 
Moreover, individually, both polymorphisms ex-
erted significant effects on all substrate activi-
Table 3. Linkage disequilibrium among Paraoxonase 1(PON1) polymorphisms 
  
  
 PON1 192 
PON1 192 
D% 
  
   
P 
PON1 55  
D% 
  
 
P 
  98.9 0.008 99.4 0.029 
PON1 55         
  92.5 <0.0001     
D%=percentage of linkage disequilibrium. P values from chi-square analysis. 
  
Table 4. Relationship between paraoxonase 1(PON1) 55 and 192 genotype and lipid serum levels 
Lipid Profile RR QQ QR P 
Total Cholesterol (mg/dL) 210.9±52.3 240.0±49.2 226.6±52.8 0.25 
HDL Cholesterol 51.8±11.4 45.3±8.0 51.2±124 0.44 
LDL Cholesterol 134.7±42.4 161.8±42.5 152.7±41.1 0.12 
 LL MM LM P 
Total Cholesterol (mg/dL) 244.1±61.3 260.2±79.2 246.7±75.6 0.34 
HDL Cholesterol 79.2±9.8 55.8±7.8 51.2±159 0.24 
LDL Cholesterol 144.9±53.4 161.8±42.5 172.3±63.3 0.52 
Values are means±standard deviations. Statistically significant (P <0.05) between compared groups. Abbreviations: 
HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
 
Table 5. Correlation of enzyme activity with PON1 192 and 55 genotype and CAVS progression 
Q192R Activity (U/L) RR QQ QR P 
  168.74±4.16 103.52±2.13 145.45±3.17 <0.001 
  
  
L55 M Activity (U/L) 
LL MM LM P 
  
 
136.56±2.45 116.93±7.23 129.77±2.92 0.12 
Echo Parameters RR QQ QR P 
AVA Reduction (cm2) -0.14±0.06 -0.07±0.06a -0.04±0.07a 0.029 
Vmax Increase (m/s) 0.19±0.16b 0.17±0.16b  0.05±0.16 0.041 
          
  LL MM LM P 
AVA Reduction (cm2) -0.17±0.06 -0.14±0.08 -0.12±0.10 0.62 
Vmax Increase (m/s) 0.17±0.19 0.19±0.13 0.15±0.11 0.84 
Values are means±standard deviations . Statistically significant (P <0.05) between compared groups.  PON activity in 
U/L=micromole of substrate hydrolysed/min. Statistically significant (P <0.05) between compared groups. (a) signifi-
cant differences compared to RR allele, (b) significant differences compared to QR allele Abbreviations: AVA: aortic 
valvular area e VMAX:transvalvular jet velocity  
PON1 and calcific aortic valve stenosis progression  
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ties. In addition, RR individuals had higher activ-
ity than QQ or QR individuals, and LL individuals, 
compared to MM and LM, had even lower PON1 
substrate activities. 
 
Paraoxonase 1 55 and 192 polymorphisms and 
CAVS progression 
 
To test the genotype effect on CAVS progression 
we evaluated the independent association be-
tween PON1 activity and genotypes as markers 
of disease progression using a multiple logistic 
regression analysis, having adjusted the model 
for predictors such as baseline AVA, sex, age, 
hypertension, diabetes mellitus, LDL choles-
terol, degree of valve calcification, LV hypertro-
phy, MR, LV end-diastolic volume, statin use, 
and baseline CAVS severity. Disease progres-
sion was considered a variable of independent 
outcome and was classified according to the 
criteria presented above. Results of the step-
wise multiple logistic regression are shown in 
Table 6. The odds ratio and associated 95% 
confidence intervals were estimated to assess 
the magnitude of the association between the 
various factors and disease progression. PON1 
activity was strongly associated with CAVS dis-
ease progression. In comparison to Q192 allele, 
the presence of R192 allele was associated 
with a 23% greater increase in CAVS disease 
progression. 
 
Discussion 
 
The present study demonstrates that (1) the 
relative allele frequency of the Q192R SNP of 
the PON1 gene differs markedly between CAVS 
patients and controls, (2) genotype has no ef-
fect on lipid profile, and (3) the variation of 
PON1 activity could explain the variation in phe-
notypic results, particularly CAVS progression.  
 
PON1 is considered anti-atherogenic because of 
its ability to destroy the inflammatory lipid per-
oxides formed by LDL oxidation [15, 42], which 
promotes many of the steps in CAVS progres-
sion. Because PON1 protects the aortic valve 
against degenerative processes by inhibiting 
LDL oxidation, decreased PON1 activity will in-
crease oxidative stress and inflammation, while 
excessive inflammation will accelerate valve 
degeneration and stenosis. To date, however, 
no specific genetic marker has been identified 
that predicts CAVS development. Whether or not 
there is a genetic contribution, in addition to 
multiple clinical atherosclerotic risk factors, to 
the development and progression of degenera-
tive CAVS remains controversial: some in vitro 
studies have shown increased protection of the 
Q 192 allele against LDL oxidation compared to 
the R192 allele [19, 42], while other studies 
have found equal [43] or decreased protection 
[44]. Because it has been suggested that poly-
morphisms negatively influence PON1 transcrip-
tion or activity (increasing the rate of atheroscle-
rosis), we analyzed the influence of Q192R and 
L55M SNPs in patients with CAVS. 
 
Previous studies associated the R192R variant 
with increased levels of serum LDL cholesterol, 
HDL cholesterol, and triglycerides [45, 46]; re-
cent studies have found either no adverse geno-
typic effect on lipoprotein variables [47-49] or a 
positive association between the Q192 allele 
and levels of HDL cholesterol and apo-I [50]. In 
addition, the physical relationship of PON1 with 
HDL and the existence of cholesterol regulatory 
elements at the PON1 locus suggest a further 
relationship of PON1 with lipoproteins, which 
may contribute to its role in vascular disease 
[51]. The biological basis for these divergent 
observations, including ours, is not clear. Our 
study suggests that Q192 PON1 bearers were 
better protected from oxidative damage caused 
by serum LDL cholesterol than were bearers of 
R192 PON1 and confirms recent in vitro find-
ings [35]. In our study, PON1 genotype Q192R 
SNP and its activity were also significantly corre-
lated with CAVS progression evaluated by AVA 
and Vmax. These results are consistent with ear-
lier findings on CAD progression and stroke [25, 
52]. 
 
The main limitation of this study is the small 
number of patients. Although our patient popu-
lation was homogeneous in terms of demo-
graphic characteristics, our results could have 
been influenced at least in part, as in many ob-
servational studies, by differences other than 
Table 6. Predictors of CAVS progression by step-
wise multiple logistic regression 
PON1 activity OR 95% CI P 
  1.35 1.1-1.7 0.003  
 R192 allele       
  1.23 1.1-14 0.002 
Statistically significant (P <0.05) between compared 
groups. Abbreviations CI: confidence interval; OR: odds 
ratio 
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genetics. As a genetic association study, there 
are certain limitations in that it cannot provide 
evidence of causative relationship between the 
Q192R genotype and outcome phenotypes. Al-
though the observed associations are consis-
tent with biological plausibility, it is likely that 
the genotypic effect may be due to linkage dis-
equilibrium with another closely linked func-
tional mutation in the PON1 gene or a nearby 
gene in the chromosome. Further, because this 
is a non-randomized and observational study, 
our results are necessarily limited by the popu-
lation frequencies of individual alleles, and gene
-gene and/or gene-environment interaction 
might have uniquely influenced the outcome 
measures in this study cohort. For these rea-
sons additional studies with a larger sample 
size are needed to confirm our observations. 
 
In conclusion, we show that the Q192R polymor-
phism of the PON1 gene and PON1 activity influ-
ence the risk of CAVS progression. However, 
knowledge of a simple aspect of the PON1 phe-
notype may not provide a complete picture of 
the role PON1 may play in metabolism and even 
in an individual’s susceptibility to cardiovascular 
disease. PON1 is controlled primarily by varia-
tion at the structural gene, but also by variation 
at several other unidentified genes. Neverthe-
less, the approach we used holds potential for 
future experimental and clinical trials designed 
to shed light on the role of polygenic factors in 
the CAVS progression. 
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